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Purpose: We tested (i) whether a renin-angiotensin system exists within the cornea, 
and (ii) its role in modulating corneal neovascularization (CNV) in vivo. 
 
Methods: Rabbit corneal fibroblast and corneal epithelial cell cultures were used in 
vitro and New Zealand White rabbits were used in vivo. Total RNA was extracted 
from cells/tissues and reverse-transcribed to cDNA using standard molecular 
biological techniques. PCR detected angiotensin converting enzyme (ACE), 
angiotensin II (AT1) receptor and angiotensin II (AT2) receptor expression. CNV was 
induced in rabbit eyes by vascular endothelial growth factor (VEGF) using micro-
pocket assay. Animals either received Enalapril, an ACE inhibitor, (3 mg/kg) or water 
IM each day for 12 days. Stereomicroscopy and immunohistochemical techniques 
were used to measure the length and number of corneal blood vessels. NIH Image 
Java software was used for quantification. 
 
Results: Rabbit corneal fibroblasts showed AT1 receptors but no ACE expression, 
whereas rabbit corneal epithelium demonstrated ACE but no AT1 receptor 
expression. Neither of these cells demonstrated AT2 receptors. Enalapril-treated 
animals showed a roughly 23 percent decrease in the number of blood vessels 
entering the cornea compared to controls at days 7 and 12. However, due to small 
sample size (n=4) this data was not found statistically significant. Surprisingly, no 
appreciable change in corneal blood vessel length was noted between the two groups.  
 
Conclusions: This study suggests a renin-angiotensin system exists within the cornea 
and plays an important role in corneal angiogenesis. More studies are needed to 
explore the therapeutic potential of Enalapril to control CNV. 
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